President Donald Trump signed Friday (Aug. 18) the FDA Reauthorization Act of 2017, a White House spokesperson tells Inside Health Policy . The legislation was praised by lawmakers on both sides of the aisle as a way to spur medical innovations and bring lower cost drugs to market. The package reauthorizes four major FDA user fee programs: the Generic Drug User Fee Amendments (GDUFA), the Biosimilar User Fee Act (BsUFA), the Prescription Drug User Fee Act (PDUFA) and the Medical...